Leerink Partnrs Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold

Leerink Partnrs downgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a hold rating in a report issued on Tuesday, Zacks.com reports.

Several other analysts have also recently commented on REGN. Cantor Fitzgerald reissued a neutral rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday, September 16th. Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an outperform rating on the stock in a research report on Tuesday. Canaccord Genuity Group reiterated a buy rating and issued a $1,152.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Wells Fargo & Company reissued an overweight rating and set a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, TD Cowen increased their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a buy rating in a report on Tuesday, July 23rd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $1,039.96 on Tuesday. The business has a 50-day simple moving average of $1,129.87 and a 200-day simple moving average of $1,033.99. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. Regeneron Pharmaceuticals has a one year low of $769.19 and a one year high of $1,211.20. The company has a market cap of $114.59 billion, a PE ratio of 30.72, a P/E/G ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same period in the prior year, the firm posted $8.79 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the transaction, the director now owns 17,882 shares of the company’s stock, valued at $18,941,329.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the transaction, the director now owns 17,882 shares in the company, valued at $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 9,270 shares of company stock worth $10,695,833 over the last ninety days. 7.48% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of REGN. Vanguard Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 1.0% in the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock worth $8,595,268,000 after acquiring an additional 91,956 shares during the last quarter. Capital World Investors raised its stake in Regeneron Pharmaceuticals by 0.5% during the fourth quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after purchasing an additional 23,146 shares during the period. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after buying an additional 213,038 shares during the last quarter. Putnam Investments LLC increased its stake in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock worth $1,063,377,000 after acquiring an additional 24,329 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 25.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after purchasing an additional 184,561 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.